AFFIN HWANG raised TOPGLOV target price to RM46.40.

AFFIN analyst ask 'Can Top Glove break RM100?'- Well, Probably.

Latest on Covid Vaccine
==================

Don't Expect First COVID-19 Vaccinations Until Early 2021: WHO Expert

Mike Ryan, head of WHO's emergencies programme said several vaccines were now in phase 3 trials and none had failed, so far, in terms of safety or ability to generate an immune response.

TP of RM480 mil is looking pretty conservative now for Supermax for Q4 judging by what Mercator achieved in similar quarter. We like surprises on the upside, so its better to keep expectations low.

MM made more money from DISTRIBUTION than PRODUCTION.
------------------------------------------------------------

"Mercator Medical has a strong distribution segment as well as production- they also sells OEM gloves bought from other manufacturers - like Kossan.

According to conference held yesterday with CEO and financial director of Mercator Medical-
" they made more money from distribution than production on Q2FY20 which ended in June. "

They are employing the same business structure as Supermax - produce, distribute their own Brand to the end user ie OBM.

Does Boustead Holdings control Pharmaniaga Bhd ?

Yes, Boustead Holdings, has a 56.09% controlling stake in Pharmaniaga. ... Boustead Holdings, in turn, is 59.45%-controlled by armed forces fund Lembaga Tabung Angkatan Tentera (LTAT).

Does Boustead Holdings control Pharmaniaga Bhd ?

Yes, Boustead Holdings, has a 56.09% controlling stake in Pharmaniaga. ... Boustead Holdings, in turn, is 59.45%-controlled by armed forces fund Lembaga Tabung Angkatan Tentera (LTAT).

Boustead's pharmaceutical division manufactures, trades, and markets pharmaceutical products.

Latest on Gloves according to J Bond.

'The World Is Not Enough' with gloves, so our glove companies operate 24 hours a day with 'No Time To Die' in producing the gloves. 'On Her Majesty's Secret Service', our gloves was sent to NHS UK. 'From Russia with Love', our gloves was delivered to Moscow hospitals. Everyone is using our gloves including' The Spy Who Loved Me'.

Latest on Vaccine according to J Bond.

'Dr. No', says vaccine is still not available, it's 'For Your Eyes Only'. Most pharmaceutical companies have used the 'Live and Let Die' method. Sometimes you will experience 'Die Another Day' & sometimes you can only hope for 'You Only Live Twice

Q4 also coming soon.

KUALA LUMPUR: Despite Malaysia's effort to help develop a Covid-19 vaccine with several other nations, it would take years before a precise vaccine is made available to the public, says Deputy Health Minister Datuk Dr Noor Azmi Ghazali.

"Although a lot of countries say that they are close to developing a vaccine, our worry is that it is still at the early stages of clinical trials.

"To get a vaccine in the near future may not happen as it will take years,"

he said when answering a supplementary question by Syed Ibrahim Syed Noh (PH-Ledang) in the Dewan Rakyat on Wednesday (July 22).

KUALA LUMPUR: Despite Malaysia's effort to help develop a Covid-19 vaccine with several other nations, it would take years before a precise vaccine is made available to the public, says Deputy Health Minister Datuk Dr Noor Azmi Ghazali.

"Although a lot of countries say that they are close to developing a vaccine, our worry is that it is still at the early stages of clinical trials.

"To get a vaccine in the near future may not happen as it will take years," he said when answering a supplementary question by Syed Ibrahim Syed Noh (PH-Ledang) in the Dewan Rakyat on Wednesday (July 22).

KUALA LUMPUR: Despite Malaysia's effort to help develop a Covid-19 vaccine with several other nations, it would take years before a precise vaccine is made available to the public, says Deputy Health Minister Datuk Dr Noor Azmi Ghazali.

"Although a lot of countries say that they are close to developing a vaccine, our worry is that it is still at the early stages of clinical trials.

"To get a vaccine in the near future may not happen as it will take years," he said when answering a supplementary question by Syed Ibrahim Syed Noh (PH-Ledang) in the Dewan Rakyat on Wednesday (July 22).

You are confused Bro. Its the price of coconuts that has fallen not Gloves.
================================================


Posted by EatCoconutCanWin > Jul 22, 2020 12:41 PM | Report Abuse

ASP drop from 25% to 5% only. Oversupply ?

Likely to be in the form of Share Dividend - 50 shares to 1000 shares held.
================================================

Posted by kennethG > Jul 22, 2020 12:31 PM | Report Abuse

what is the estimated divident supermax might award the shareholders?

Absolutely Bro.

Its purely HYPE unlike Gloves which is driven by fantastic earnings.
===============================
Posted by staypositive > Jul 22, 2020 12:27 PM | Report Abuse

Those who trapped at high price on Pharma will get burned...

SUPERMAX QTR 4 RESULT FORECAST

PAT RM313 million - PAT RM521 million (AVG - RM 417 million)

TP of RM24-26 within sight before release of Q4

Be patient folks.
=============================================
24.00 with expected profit 71 x 5.11 = 396 mil (QTR 4) 5.58x

26.00 with expected profit 71 x 6.04 = 429 mil (QTR 4) 6.04x

Well said and totally agree with you Sifu OTB.
=============================
Posted by OTB > Jul 22, 2020 10:21 AM | Report Abuse

Posted by 817065 > Jul 22, 2020 8:39 AM | Report Abuse

If any of you trust KYY and OTB, then you will die poor....this is based on past history.
-------------------

Want to attack me, not in Supermx forum.
I recommend to buy Supermx to all investors at 3.60.
I want to measure my performance in actual result.
I do not wish everyone to trust me.
I know that in 2020, everyone who trusted me are laughing all the way to the bank.
I had created at least 30 to 50 millionaires in 2020, will they die poor ?
Likewise, in 2015, 2016, 2017, 2019.
I did poorly in 2018.

I sold my Supermx when the share price hits my target price.
I did not disturb any investor in this forum.
I just inform my subscribers to sell because they paid for my service.

I told my subscribers that I bought back some Supermx at 14.52.
I still hold them awaiting Q4 2020 result.
I did not disturb anyone here in this Supermx forum.

No reason to attack me.
Thank you.

Supermax business strategy is not well appreciated by analyst/IBs

Supermx controls the entire retail value chain from factory to the end customer by itself while THK focus on low price high volume to compete with one another. There is no key business strategic differentiation amongst THK...and in this situation only the biggest volume amongst them will shine.

It is the strongest contender so far and Its meteoric rise cannot be evaluated by how many time it has increased... but whether its can yield the necessary results to qualify for the increase and further rise...

TG's Q3 PAT result was 347mil... U can guess where Supermax Q4 PAT shall be. Try not to be distracted by the noise.

============================================
Posted by Lee Kok Wee > Jul 21, 2020 10:24 PM | Report Abuse

Why so many IB look good at Top Group instead of Supermx ? Study today news

AFFIN HWANG raised target price to RM46.40. Bull Case Scenario RM110.20
RHB revised from RM28.88 to RM33.30
PB bank revised from RM23 to RM26.70
MIDF revised from RM26.12 to RM27.90

Hai Ya, when you have freetospeak, who needs Uncle KYY?. Go for the genuine Sifu and not the slippery one. LOL.

Breaking news

RHB raised SUPERMX target price to RM21.80
Publish date: Tue, 21 Jul 2020, 10:47 AM

Breaking news


RHB raised SUPERMX target price to RM21.80
Publish date: Tue, 21 Jul 2020, 10:47 AM

This a very good article by @Wok

========================

Posted by Wok > Jul 20, 2020 8:56 PM | Report Abuse

Amongst these THKS... Supermax hv always been the underdog due to its different approach in business strategy that is not well appreciated by analyst.

Supermx controls the entire retail value chain from factory to the end customer by itself while THK focus on low price high volume to compete with one another. There is no key business strategic differentiation amongst THK...and in this situation only the biggest volume amongst them will shine.

Supermx hv overtaken Kossan Harta and now chasing TG after racing up from the bottom. It is the strongest contender so far and Its meteoric rise cannot be evaluated by how many time it has increased... but whether its can yield the necessary results to qualify for the increase and further rise...

TG's Q3 PAT result was 347mil... U can guess where Supermax Q4 PAT shall be. Try not to be distracted by the noise.

This a very good article by @Wok which deserves a second mention.

========================

Posted by Wok > Jul 20, 2020 8:56 PM | Report Abuse

Amongst these THKS... Supermax hv always been the underdog due to its different approach in business strategy that is not well appreciated by analyst.

Supermx controls the entire retail value chain from factory to the end customer by itself while THK focus on low price high volume to compete with one another. There is no key business strategic differentiation amongst THK...and in this situation only the biggest volume amongst them will shine.

Supermx hv overtaken Kossan Harta and now chasing TG after racing up from the bottom. It is the strongest contender so far and Its meteoric rise cannot be evaluated by how many time it has increased... but whether its can yield the necessary results to qualify for the increase and further rise...

TG's Q3 PAT result was 347mil... U can guess where Supermax Q4 PAT shall be. Try not to be distracted by the noise.

Great analysis Sifu freetospeak. You have been spot on in your analysis all the way. A thoroughbred among all the Sifus.

There are a variety of different investing philosophies within the responsible investing realm. One method you may have been hearing about more and more is ESG investing.

Lots of big funds are looking for ESG compliant supplier and stock. I feel Supermax is working towards achieving this goal. ie ESG compliant stock.

"ESG" stands for environmental, social, and governance. Investors who employ this strategy examine criteria within these three categories to analyze stocks. Combining the ESG lens with more traditional stock analysis techniques is known as ESG integration. Anyone can join the swelling ranks of ESG investors by simply learning more and then using this framework in making future investing decisions.

Moderna said it would begin its Phase II/III trial... a trial that would be completed on October 2022. Not only is this 2 years in the future but they still don't have evidence that their vaccine would work.
Presidents and CEO may demand a vaccine now but they won’t get it any sooner. Scientist cannot work more than 24 hours in a day nor can cells grow any faster. Yet, market sentiment is like an easily panicked goat and about as intelligent as one too.

========================================================
Posted by Arsenewenger8383 > Jul 20, 2020 5:01 PM | Report Abuse

They r in 3rd phase in large scale testing in Brazil.. Russia already confirmed to get this vaccine by september..

The main purpose of the bonus issue is to REWARD shareholders who never wavered and kept their BELIEVE in SUPERMAXX.

Hallelujah!

NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) : BONUS ISSUES SUPERMAX CORPORATION BERHAD ("SUPERMAX" OR THE "COMPANY") PROPOSED BONUS ISSUE OF UP TO 1,360,309,760 NEW ORDINARY SHARES IN SUPERMAX ("SUPERMAX SHARE(S)" OR "SHARE(S)") ("BONUS SHARE(S)") ON THE BASIS OF 1 BONUS SHARE FOR EVERY 1 EXISTING SUPERMAX SHARE HELD ON AN ENTITLEMENT DATE TO BE DETERMINED LATER ("PROPOSED BONUS ISSUE OF SHARES")
SUPERMAX CORPORATION BERHAD


Type Announcement
Subject NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
BONUS ISSUES
Description SUPERMAX CORPORATION BERHAD ("SUPERMAX" OR THE "COMPANY")

PROPOSED BONUS ISSUE OF UP TO 1,360,309,760 NEW ORDINARY SHARES IN SUPERMAX ("SUPERMAX SHARE(S)" OR "SHARE(S)") ("BONUS SHARE(S)") ON THE BASIS OF 1 BONUS SHARE FOR EVERY 1 EXISTING SUPERMAX SHARE HELD ON AN ENTITLEMENT DATE TO BE DETERMINED LATER

("PROPOSED BONUS ISSUE OF SHARES")
On behalf of the Board of Directors of Supermax, UOB Kay Hian Securities (M) Sdn Bhd ("UOB Kay Hian") wishes to announce that Supermax proposes to undertake a bonus issue of up to 1,360,309,760 new Bonus Shares on the basis of 1 Bonus Share for every 1 existing Supermax Share held on an entitlement date to be determined later.



Please refer to the attachment for further details on the Proposed Bonus Issue of Shares.





This announcement is dated 20 July 2020.

The comparison between TESLA and SUPERMAX is pretty frivolous, just take a look at their
market capitalisation-

TESLA................RM1.18 Trillion (278 B -USD)

SUPERMAX........RM24.1 Billion (5.6 B- USD)

The comparison between TESLA and SUPERMAX is pretty frivolous, just take a look at their
market capitalisation-

TESLA................RM1.18 Trillion (278 B -USD)

SUPERMAX........RM24.1 Billion (5.6 B- USD)
=======================================================

(July 19): A relatively low-tech stock trade is making Tesla Inc.’s dizzying rally look like an under-performance.

In Southeast Asia, makers of rubber gloves are attracting more investor fervor than even the electric cars and flame throwers of Elon Musk. Top Glove Corp. is up 389% this year in Kuala Lumpur, the most on the MSCI Asia Pacific Index, while Supermax Corp. has leaped more than 1,000%, compared with Tesla’s 259%. That’s due to the boom in glove demand thanks to the coronavirus pandemic, aided by a short-selling ban in Malaysia till year-end.

“The rally in glove makers reminds many of Tesla but the sector’s earnings outlook is more certain than that of Tesla,” said Ross Cameron, a fund manager at Northcape Capital Ltd., which overseas about $7 billion in assets globally. The short-selling ban has had a minor contribution to the rally while “we expect the sector to report significantly more than 100% earnings growth next year,”

Cimb recently made a forecast of RM356m.for the Q4. Some of us would consider this as humble or rather conservative, thats a good move, its better not to be over optimistic .

Here is a rough estimate for the following 4 quarters( FYE 2021)-
Q1..........RM450
Q2..........RM495
Q3..........RM545
Q4..........RM598- Assuming ASP peak in the 4th Q.

Thus, for FYE2021 PAT is conservatively estimated at Rm2,088 billion.
This work out to a EPS of RM1.54.

PE of 20.....RM30.80.
PE of 25.....RM38.50
PE of 30.....RM46.20

============================================================

Qtr 1 at least 500m x 4 = 2 BILLION considering asp peaked(unlikely) n no increase in caps(aug got new line). 1.5 billion is too little.

@freetospeak sifu, u mean Q1 2021 pure profit will be rm2B???? Please advise..omg..need top up more on monday before shoot up to rm30 at least
18/07/2020 10:05 PM

Mortgaging your cat to invest in Topglove
Author: pBlue | Publish date: Sun, 19 Jul 2020, 1:17 PM

The fundamentals have finally re-exerted themselves. And the reality of Topglove being the world's largest glove manufacturer during 1 of 3 pandemic of the last century, which is still without a vaccine, has calmed investor fears. Share prices are up by 17% from the weekday lows and the irrational Bears have receded. However another particular cry has started to occur, that from Bulls, who make humorous or flippant calls for people to put all their money into glove stocks, perhaps to the point of mortgaging their cat.

I find it funny myself, but that being said, I am concerned that some people might actually do that, put all their money that they can into glove shares. From a financial point of view, investing all your money in Topglove certainly promises the a large rate of return, which even now may still reach 160%. However I would be a little more cautious. The market is not exactly rational and neither are some of the actions of nations in this pandemic.

For example, we saw a sell off from RM25.16 to RM20.50 just because Moderna said it would begin its Phase II/III trial... a trial that would be completed on October 2022. Not only is this 2 years in the future but they still don't have evidence that their vaccine would work. Then we had a US ban on half of Topglove exports into the country over a mostly resolved case. This ban is an action that the US cannot possibly afford or sustain, as 25% of its 50 States are less than 30 days away from exhausting their PPE supplies.
Yet how many people lost money last week’s selling at 20.50, 19.70 and 19.60? All those losses happened in a Friday (10/7/2020) to Friday (17/10/2020) period that saw a rise of RM1.06 from RM21.92 to RM22.98.

The fundamentals of Topglove and all large major glove companies in Malaysia are presently iron solid, impossible to deny as we can see the actual driver of glove demand, Covid19 growing exponential on the news, backed by biology, medical practice and human physics. Presidents and CEO may demand a vaccine now but they won’t get it any sooner. Scientist cannot work more than 24 hours in a day nor can cells grow any faster. Yet, market sentiment is like an easily panicked goat and about as intelligent as one too.

In the long term, TG share prices will rise, mirroring the fundamental increase in demand for more gloves as the world both fights the Covid19 pandemic and struggles to keep businesses open. But in the short term anything can happen. There are over 500 phase I/II trials, and over 300 Phase II/III trials of various treatments, some of which are really far out including BCG vaccination, which if truly protective, no Malaysian would have caught Covid19 and honey… Yes, honey. Just goes to show that about every company is running their own Covid19 trial to make a buck. Maybe next month, we get rumors that Egyptian Honey can cure Covid19 and for some reason everyone believes it, panics and cause share price to fall -30%.

Can you stay rational enough in a panicked sell off to say "This is stupid!" and avoid joining in yourself. It is harder to stay rational if you put all your net worth into one investment and just watched 30% of its value vanish in a matter of days. This July 14 panic attack lasted 4 trading days. The attack before that lasted 11 trading days. IBoth saw a peak to trough of -28%. And the attack before that, Jun 2, lasted 2 trading days and saw a 53% decline.

I am sure most of us have no need from this article and will find the message common sense. But for those just entering the stock market, a small suggestion, don’t put in so much money that you have trouble staying rational during a dip. The coming quarters for Topglove (and other major glove companies) are going to be some of the most profitable in their history and it would be a shame if the only people who profited from it are foreign institutional investors, buying shares cheap off panicked Malaysian retail investor. Don't morgage your cat to invest in Topglove, it would be hard to think rationally.

The Rm 4.80 target price for Comfort Glove conservative to say the least.

Total for the year profit Rm 275.3 million

Total issued shares 580 million

EPS 47 sen

A fair valuation at PE of 15 is Rm7.05.

Comfort is a laggard glove stock- accumulate.

Supermax: Sellers are caught - Koon Yew Yin

Author: Koon Yew Yin | Publish date: Sat, 18 Jul 2020, 10:53 AM

Yesterday alone it shot up Rm 2.80 with an above average volume of 54 million shares traded. This is a clear sign that many rich investments have been buying aggressively. On 10 July Mr Sim, RHB Perak manager can confirm that I bought 995,500 Supermax shares at Rm 13.25. As a result, the share price has been shooting up like rocket.

It is unwise to sell even at the last closing price of Rm 17.70 because it will continue to go up higher and higher until the Covid 19 pandemic is under control.

Many investors who sold earlier are disappointed that they cannot buy back at cheaper prices.

I feel its Local Funds esp the Syariah Compliant Funds, Investment Banks & maybe foreign funds.
=================================================
Posted by chopstick > Jul 18, 2020 10:14 AM | Report Abuse

sometimes i just wondering who is buying and supporting at such a high price. i doubt not many at this forum. many supporting with posting, bank, investors, company, directors. or ikan besar. any comment?

Brilliant Calvin - Don't forget the poor/needy. God bless..
===========================================

Posted by calvintaneng > Jul 18, 2020 10:07 AM | Report Abuse

Supermax C87

Bought 34.5 sen
Now Rm6.39

Up a whopping 1,850% in this Once a Century Glove Bull run

Really unbelievable !!!

Certainly not a bubble- Just analyse the figures below.
====================================
(many thanks @freetospeak.for the figures)

1.80 with profit 30 million (QTR 2)
rise to
4.30 with profit 71 million (QTR 3) 2.38x
rise to
16.00 with expected profit 71 x 3.72 = 264 mil (QTR 4) 3.72x

18.00 with expected profit 71 x 4.18 = 297 mil (QTR 4) 4.18x

20.00 with expected profit 71 x 4.65 = 330 mil (QTR 4) 4.65x

22.00 with expected profit 71 x 5.11 = 363 mil (QTR 4) 5.11x

24.00 with expected profit 71 x 5.11 = 396 mil (QTR 4) 5.58x ( Q4 is expected @ 380 mil)

26.00 with expected profit 71 x 6.04 = 429 mil (QTR 4) 6.04x

28.00 with expected profit 71 x 6.51 = 462 mil (QTR 4) 6.51x

RHB & CIMB raises TP on Supermax.

CIMB raises SUPERMAX TP to ................ RM19.60
RHB raises SUPERMAX TP to.............. RM 18-88

STEEPER ASP INCREASES AT DISTRIBUTION LEVEL

BUY- with raised TARGET PRICE

1- Gloves shortages have worsened, as COVID-19 cases in the US have surged 24% MTD. We increase our earnings estimates and TP due to higher ASPs. As Supermax Corp has its own distribution channel in the US, we expect its earnings to outperform peers. Our new TP reflects 27.5x FY21F (Jun) P/E – a 23% discount against the sector average due to SUCB’s smaller market cap/ liquidity.

2- Gloves demand estimates have increased, as COVID-19 cases in the US surged 24% MTD. Over the past five days (8-12 Jul), the number of new cases daily has surged >60,000. As the US is the biggest gloves consumer globally, stubbornly high number of COVID-19 cases means that gloves demand should continue to rise.

3- Gloves shortages have worsened. Within a period of two weeks, the number of new COVID-19 cases in the US and Brazil has increased more than expected. As a result, we estimate gloves demand there has increased and caused further depletion in global stock levels. Our estimate shows that levels should have declined by another 2% to 10.8bn pieces globally.

4-ASP assumptions increased. Our channel checks also reveal the shortage of certain raw materials used in gloves manufacturing. This has capped near-term supply. We have increased FY21-22 ASP assumptions by 2-9%. This increase is higher than SUCB’s peers due to its distribution channels in eight countries, including the US and Brazil. These countries are still registering high new COVID-19 cases. FY20F earnings remain unchanged, as the financial year ended in June.

5-BUY with a higher TP. We have increased our FY21F-23F earnings forecasts by 14-19%. In the short term, 1QFY21 core earnings should show significant improvement QoQ, as ASPs are on an increasing trend. Post COVID-19, SUCB’s earnings growth outlook remains positive, as we expect gloves demand to continue the usual uptrend growth of 8-10% due to higher hygiene awareness globally.

Here you go another upgrade today -

CIMB raised SUPERMX target price to RM19.60

LATEST- RHB RAISES SUPERMAX TP TO RM 18-88

STEEPER ASP INCREASES AT DISTRIBUTION LEVEL

BUY- TARGET PRICE RM18.88.

1- Gloves shortages have worsened, as COVID-19 cases in the US have surged 24% MTD. We increase our earnings estimates and TP due to higher ASPs. As Supermax Corp has its own distribution channel in the US, we expect its earnings to outperform peers. Our new TP reflects 27.5x FY21F (Jun) P/E – a 23% discount against the sector average due to SUCB’s smaller market cap/ liquidity.

2- Gloves demand estimates have increased, as COVID-19 cases in the US surged 24% MTD. Over the past five days (8-12 Jul), the number of new cases daily has surged >60,000. As the US is the biggest gloves consumer globally, stubbornly high number of COVID-19 cases means that gloves demand should continue to rise.

3- Gloves shortages have worsened. Within a period of two weeks, the number of new COVID-19 cases in the US and Brazil has increased more than expected. As a result, we estimate gloves demand there has increased and caused further depletion in global stock levels. Our estimate shows that levels should have declined by another 2% to 10.8bn pieces globally.

4-ASP assumptions increased. Our channel checks also reveal the shortage of certain raw materials used in gloves manufacturing. This has capped near-term supply. We have increased FY21-22 ASP assumptions by 2-9%. This increase is higher than SUCB’s peers due to its distribution channels in eight countries, including the US and Brazil. These countries are still registering high new COVID-19 cases. FY20F earnings remain unchanged, as the financial year ended in June.

5-BUY with a higher TP. We have increased our FY21F-23F earnings forecasts by 14-19%. In the short term, 1QFY21 core earnings should show significant improvement QoQ, as ASPs are on an increasing trend. Post COVID-19, SUCB’s earnings growth outlook remains positive, as we expect gloves demand to continue the usual uptrend growth of 8-10% due to higher hygiene awareness globally.

Close to 1.6 mil shares done at Rm17.70 ie closing price. Thats colossal !

Shouldn't be a problem looking at its velocity.

===================================

Posted by DKinvest727 > Jul 17, 2020 4:22 PM | Report Abuse

Can go to 18?

Gosh, are you a comedienne by any chance.?
=========================================
Posted by JBond007 > Jul 17, 2020 2:16 PM | Report Abuse

'The World Is Not Enough' with gloves, so our glove companies operate 24 hours a day with 'No Time To Die' in producing the gloves. 'On Her Majesty's Secret Service', our gloves was sent to NHS UK. 'From Russia with Love', our gloves was delivered to Moscow hospitals. Everyone is using our gloves including' The Spy Who Loved Me'.

J Bond- you are absolutely funny.
===========================================
Posted by JBond007 > Jul 17, 2020 2:12 PM | Report Abuse

According to 'Dr. No', vaccine is still not available, it's 'For Your Eyes Only'. Most pharmaceutical companies have used the 'Live and Let Die' method. Sometimes you will experience 'Die Another Day' & sometimes you can only hope for 'You Only Live Twice'.

Moderna COVID-19 vaccine induced adverse reactions in 'more than half' of trial participants
Bad news for mankind esp. D Trump, good news for PPE manufacturers.
=========================================================
A highly anticipated clinical trial for a potential COVID-19 vaccine managed in part by the American drug company Moderna has resulted is some adverse effects in more than half of the trial's participants, with one test group reporting "severe" symptoms.

Miracles do happen Bro.
=============================

Posted by johnny cash > Jul 17, 2020 12:22 PM | Report Abuse

IT WILL GO 50..DO YOU BELIEVE IN LAWS OF MIRACLES???

At the rate its moving, I won't be surprised.
====================================
Posted by MichelleNg > Jul 17, 2020 12:19 PM | Report Abuse

Go go go limit up.

After navigating thru so many headwinds Supermaxx is showing its superiority, strength and resilience. Investors really need balls of steel and a strong heart.LOL

The TG saga has dented its reputation esp with regard to Labour issues.The bad publicity is going to hurt TG immensely. Most western buyers will look into this issue and may in future divert their purchases to unblemished manufacturers such as Supermax. Hence, Supermax will greatly benefit from Top Glove's mis-step or rather misfortune. Its business structure (OBM- plus marketing & distribution) is designed to reap max profitability from the pandemic. Supermax certainly deserves premium pricing. Will Supermax be the top glove manufacturer in terms of market cap? Time will tell. Just my 2 cents.